Search
Menu
Home
HTB
2023
June
HTB
June 2023
Contents
Editorial
HTB May/June 2023: HIV and implementation science
Non technical HTB news: 12 stories from May/June issue
New i-Base pocket leaflets (May 2023)
Conference reports
BHIVA Annual Conference 2023 (BHIVA 2023)
UK cascade data cautions UNAIDS 95:95:95 targets: re-engaging people in care
Overview of weight gain, integrase inhibitors and ART
Selected webcasts from BHIVA 2023
30th CROI (CROI 2023): final reports
Viral reservoir increases on long-term ART: new strategies for a cure
Microbiota biomarkers might predict risk of HSIL progression: succinyl-CoA and cobalamin
CROI overviews by BHIVA and IAS-USA
Antiretrovirals
ART increases life expectancy by 30 to 40 years: impact of CD4 count, sex and calendar year
Guidelines
BHIVA guidelines modify assessment of cardiovascular risk (2023)
BHIVA guidelines on non-TB mycobacteria (NTM)
mpox (monkeypox)
US studies report mpox vaccine efficacy from single- vs double-dose might only be 36% vs 66%
Coinfections and complications
No benefit on HIV-associated neurocognitive impairment from CNS-penetrating ART
First successful liver transplant from living donor with HIV/HCV coinfection: surgical video online
Review of idiopathic lymphocytopenia
HIV prevention and transmission
NHS England approves use of F/TAF as alternative PrEP
Drug resistance
Tracking HIV A6 strain in Europe: implications for injectable CAB-LA for treatment or PrEP
COVID-19: HIV and COVID-19 coinfection
Tenofovir reduces risk of COVID-19 in pre-vaccine studies
PDFs
HTB: no. 5/6 (May/June 2023) PDF download
HTB RSS
Early access
Detailed results from Palm007 study: no clinical impact of tecovirimat against mpox clade 1
6 January 2025
Tecovirimat news continues: Japan approval includes mpox indication
2 January 2025
Looking back through 2024 and forward to 2025…
1 January 2025
Transient impact of lenacapavir against MDR HIV-2 without other active ART
1 January 2025
All early access reports
Current issues
January 2025
December 2024
November 2024
Back issues
Special report
Detailed results from Palm007 study: no clinical impact of tecovirimat against mpox clade 1
6 January 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate